Plus Therapeutics, Inc.
PSTV
$0.2025
-$0.1061-34.38%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -36.85% | 7.54% | 17.42% | -31.01% | 231.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -36.85% | 7.54% | 17.42% | -31.01% | 231.42% |
| Cost of Revenue | -36.45% | -21.76% | 14.64% | 95.28% | -7.38% |
| Gross Profit | 35.82% | 47.74% | -11.89% | -444.24% | 56.16% |
| SG&A Expenses | 28.29% | 31.51% | 19.97% | 14.50% | -1.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.66% | 2.73% | 17.01% | 48.80% | -4.82% |
| Operating Income | -7.18% | -1.09% | -16.86% | -148.12% | 30.14% |
| Income Before Tax | -433.61% | -2.44% | 10.72% | -98.38% | 32.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -433.61% | -2.44% | 10.72% | -98.38% | 32.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -433.61% | -2.44% | 10.72% | -98.38% | 32.13% |
| EBIT | -7.18% | -1.09% | -16.86% | -148.12% | 30.14% |
| EBITDA | -7.82% | 0.16% | -16.43% | -165.19% | 31.11% |
| EPS Basic | -58.31% | 41.40% | 63.35% | 23.43% | 63.57% |
| Normalized Basic EPS | -58.31% | 41.39% | 63.34% | 23.41% | 63.57% |
| EPS Diluted | -58.31% | 41.40% | 63.00% | -20.32% | 63.57% |
| Normalized Diluted EPS | -58.31% | 41.39% | 63.34% | 53.67% | 63.57% |
| Average Basic Shares Outstanding | 237.06% | 74.81% | 143.56% | 159.06% | 86.28% |
| Average Diluted Shares Outstanding | 237.06% | 74.81% | 143.56% | 328.11% | 86.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |